ストックスクリーナーアプリを入手
24.67
2.45%
0.5433
Septerna Inc (SEPN) 最新ニュース
Septerna to Present at Bank of America Securities Health Care Conference - The Manila Times
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus - MarketBeat
Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest - MarketBeat
Stifel Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $43 - Moomoo
Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor - Stock Titan
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates - MSN
Septerna (SEPN) price target increased by 34.39% to 46.41 - MSN
Are Options Traders Betting on a Big Move in Septerna Stock? - MSN
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Top Executives at Septerna, Inc. Make Bold Stock Purchases! - TipRanks
SEPN (Septerna Inc.) shares rise 7.46 percent after Q4 2025 loss lands narrower than consensus analyst estimates. - Xã Thanh Hà
Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial? - Sahm
Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN) - The Globe and Mail
Truist Financial Maintains Septerna(SEPN.US) With Buy Rating - Moomoo
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares - MarketBeat
Septerna Inc (SEPN) president and COO sells $97k in stock - Investing.com
[Form 4] Septerna, Inc. Insider Trading Activity - Stock Titan
Assessing Septerna (SEPN) Valuation After First Dosing In SEP-479 Phase 1 Trial - Sahm
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target - TipRanks
Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy? - Sahm
HC Wainwright Reiterates Buy Rating for Septerna (NASDAQ:SEPN) - MarketBeat
H.C. Wainwright reiterates Septerna stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com - Investing.com South Africa
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - Exchange Bitget
SEPTERNA INCPHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027 - Moomoo
Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com - Investing.com Australia
Septerna doses first patients in SEP-479 trial - TipRanks
Insider Buy: Is Septerna Inc part of any ETF2026 Sector Review & Risk Controlled Stock Alerts - baoquankhu1.vn
Septerna (SEPN) Initiates Phase 1 Trial for Hypoparathyroidism T - GuruFocus
Movement Recap: Will Septerna Inc benefit from current market trendsWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Septerna Begins Phase 1 Clinical Trial of SEP-479, an Oral PTH1R Agonist, for Hypoparathyroidism Treatment – Data Expected Late 2026/Early 2027 1 - Minichart
Septerna Begins Phase 1 Trial of Oral SEP-479 - TipRanks
Septerna doses first patient in SEP-479 hypoparathyroidism trial - Investing.com
Septerna begins Phase 1 trial of oral PTH1R agonist SEP-479; Phase 1 data expected late 2026–early 2027 - TradingView
Septerna (Nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism - Stock Titan
Septerna starts human testing of an oral drug for a lifelong disorder - Stock Titan
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):